Stock MARKSANS MARKSANS PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Marksans Pharma Limited Bombay S.E.

Equities

MARKSANS

INE750C01026

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:53 2024-07-12 am EDT 		5-day change 1st Jan Change
189 INR -1.72% Intraday chart for Marksans Pharma Limited +0.59% +17.50%
Jul. 02 Marksans Pharma Gets UK Regulator's Nod for Two Products MT
May. 31 Transcript : Marksans Pharma Limited, Q4 2024 Earnings Call, May 31, 2024

Valuation

Fiscal Period: March 2019 2023 2024 2025 2026
Capitalization 1 10,212 31,903 85,720 - -
Enterprise Value (EV) 1 10,212 31,903 68,836 85,720 85,720
P/E ratio 13.3 x 11 x 22 x 21.5 x 17.7 x
Yield - - - - -
Capitalization / Revenue 1.02 x - 3.16 x 3.21 x 2.7 x
EV / Revenue 1.02 x - 3.16 x 3.21 x 2.7 x
EV / EBITDA 7.47 x - 15 x 15.1 x 12.5 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - 3.33 x 3.53 x 2.98 x
Nbr of stocks (in thousands) 409,314 453,164 453,164 - -
Reference price 2 24.95 70.40 189.2 189.2 189.2
Announcement Date 5/29/19 5/30/23 5/30/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2023 2024 2025 2026
Net sales 1 10,001 - 21,774 26,699 31,790
EBITDA 1 1,368 - 4,586 5,687 6,835
EBIT - - - 5,412 6,593
Operating Margin - - - 20.27% 20.74%
Earnings before Tax (EBT) 1 - - 4,235 5,304 6,498
Net income 1 804.4 2,653 3,137 3,966 4,861
Net margin 8.04% - 14.41% 14.85% 15.29%
EPS 2 1.870 6.410 6.920 8.800 10.70
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 5/29/19 5/30/23 5/30/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 Q3
Net sales 1 5,525
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) 1 1,179
Net income 1 865
Net margin 15.66%
EPS 2 1.910
Dividend per Share -
Announcement Date -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) 15.9% - 16.5% 16.3% 16.9%
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share 2 - - 45.60 53.60 63.40
Cash Flow per Share - - - - -
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 5/29/19 5/30/23 5/30/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
189.2 INR
Average target price
215 INR
Spread / Average Target
+13.66%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
NOVARTIS AG Stock Novartis AG
+17.90% 228B
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MARKSANS Stock
  4. MARKSANS Stock
  5. Financials Marksans Pharma Limited